According to The Insight Partners' research, the Europe Biopharmaceutical Contract Manufacturing Market was valued at US$ 11,420.5 Million in 2024 and is expected to reach US$ 27,678.2 Million by 2031, registering a CAGR of 13.6% from 2025 to 2031.
Increasing demand for personalized medicine and increasing demand for cost efficiency and flexibility are among the critical factors attributed to driving the Europe biopharmaceutical contract manufacturing market growth.
Personalized medicine offers a significant opportunity by offering tailored treatments that are designed to meet the unique genetic profiles, environments, and lifestyles of individual patients. This approach is experiencing increased adoption owing to advancements in genomics, biotechnology, and diagnostics, allowing for more precise and effective treatments. The constant developments in personalized medicine are creating demand for specialized, flexible, and scalable manufacturing solutions. These developments have increased the collaborations with contract manufacturing organizations (CMOs) to bring these therapies to market. Personalized therapies often require tailored approaches that involve more flexible manufacturing processes, which include gene therapies, cell therapies, and precision oncology treatments. As a result, biopharmaceutical companies are increasingly turning to CMOs that offer the expertise and capacity to handle these specialized manufacturing needs. In August 2025, MS Pharma opened the Middle East's first biologics manufacturing facility in Riyadh, Saudi Arabia. This $50 million investment received GMP approval from the Saudi Food and Drug Authority (SFDA) and is designed to meet EMA and US FDA standards. The facility specializes in monoclonal antibodies and complex peptides, providing contract manufacturing services to global partners looking to enter the MENA, EU, and US markets. This development highlights Saudi Arabia's commitment to improving its biopharmaceutical capabilities to meet the growing demand for personalized medicine.
The growing demand for personalized medicine emphasizes the need for efficient, scalable manufacturing processes that can adapt to the production of highly individualized treatments. For instance, gene therapies such as Kymriah (developed by Novartis) and Yescarta (from Gilead) are personalized medicines that have been successfully developed and commercialized. CMOs with the right infrastructure provide these treatments, as they require unique manufacturing processes. Moreover, CMOs that can offer specialized services to produce cell-based therapies or gene-editing technologies, such as CRISPR-based treatments, are well-positioned to benefit from the personalized medicine trend. As companies move toward smaller batch sizes, flexibility, and customization, CMOs play a vital role in ensuring that these treatments are efficiently and cost-effectively produced, thereby creating lucrative opportunities for the market during the forecast period.
On the contrary, the tightened budget and economic uncertainty hamper the growth of the Europe biopharmaceutical contract manufacturing market.
Europe Biopharmaceutical Contract Manufacturing Market Segmentation Analysis:
- By Product Type, the Europe Biopharmaceutical Contract Manufacturing Market is segmented into Biologics and Biosimilar. The Biologics segment is projected to expand at 13.7% CAGR during 2025 - 2031.
- By Source, the Europe Biopharmaceutical Contract Manufacturing Market is segmented into Microbial and Mammalian. The Microbial segment is projected to expand at 13.8% CAGR during 2025 - 2031.
- By Application, the Europe Biopharmaceutical Contract Manufacturing Market is segmented into Commercial and Clinical. The Commercial segment is projected to expand at 14.1% CAGR during 2025 - 2031.
- By Therapeutic Area, the Europe Biopharmaceutical Contract Manufacturing Market is segmented into Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others. The Oncology segment is projected to expand at 14.3% CAGR during 2025 - 2031.
By country, the Europe Biopharmaceutical Contract Manufacturing Market is categorized into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany is projected to expand at 14.0% CAGR during 2025 - 2031.
Key players operating in the Biopharmaceutical Contract Manufacturing Market are Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co Ltd, WuXi Biologics Inc, Merck KGaA, Ajinomoto Co Inc, Cytiva, and AGC Biologics AS, among others.
- In 2025, Boehringer Ingelheim's biopharmaceutical facility in Shanghai, China, meets the conditions to participate in a regulatory reform promoting segmented manufacturing of biological products by the local authorities. The reform, led by the Chinese medicine authority, the NMPA (National Medical Products Administration), aims to enhance control, efficiency, and flexibility in the production process. As one of the few contract manufacturing organizations qualified for the pilot period, Boehringer Ingelheim BioXcellence is expanding its service portfolio in China, offering distinct service packages for different segments in biopharmaceutical production and enabling the sustainable global supply of medications to patients.
- In 2024, SyVento Biotech opened its new mRNA manufacturing facility, a FlexFactory delivered by Cytiva, spanning over 7,000 m2 and including lab and production areas, offices, and shared spaces. This development represents a significant milestone for SyVento Biotech, enabling the CDMO to accelerate and enhance its service offerings to medicine manufacturers. It also establishes SyVento Biotech as a pioneer in the Polish market, as it is the first mRNA FlexFactory in the country and the first in Europe equipped with the Historian automation system.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com